Read More Pharma Industry News Zymeworks (ZYME) to buy Theravance (TBPH) for $929m in cash plus ampreloxetine CVR Zymeworks (ZYME) to acquire Theravance (TBPH) for $17/share plus CVR, $929M equity value. Non-recourse OMERS financing minimises ZYME's cash at risk. byVenkateshJuly 1, 2026